BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
ALAMEDA, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank">$BTX</a> <a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank">#AMD</a>--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new Thaw-and-Inject formulation of OpRegen®, the Company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing Phase I/IIa clinical study for the treatment of dry age-related macular deg